BRIEF: Everest Medicines advances with major licensing deal, new drug application approval
Everest Medicines Ltd. (1952.HK) last Thursday announced an exclusive licensing agreement to commercialize Micot’s MT1013 for the treatment of secondary hyperparathyroidism (SHPT), worth up to 1.24 billion yuan ($179 million).…
Everest Medicines drives growth with AI-powered mRNA pipeline
The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine’s EVM14 cancer vaccine…
BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial
Everest Medicines (1952.HK) announced on Wednesday that its EVER001, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor for treatment of primary membranous nephropathy (pMN), showed positive results in its…
A McDonald’s Valuation Downsize, and New Medical Plan Additions
The value of McDonald's China operation has plunged by more than half in the last year. And 91 companies got their drugs added to China's national health plan By Doug…
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
Nefecon’s addition to China’s NRDL will increase its reach and market share, lifting the drug’s competitive advantage and brand recognition Key Takeaways: Everest Medicines’ Nefecon kidney drug was approved for…
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
The innovative drug maker’s stock jumped more than 18% in a single day on high hopes for inclusion of its blockbuster new drug, Nefecon, in China’s national reimbursement drug list…
FAST NEWS: Everest Medicines loss widens on drug commercialization
The Latest: Everest Medicines Ltd. (1952.HK) announced Tuesday its revenue for the first half of this year surged about 33 times to 302 million yuan ($42.3 million), while its net loss jumped 49%…
Recent Articles
RELATED ARTICLES
-
RemeGen scores out-licensing triple play with AbbVie deal
9995.HK688331.SHG - Jacobio Pharma poised to turn a profit from precision cancer drugs
-
Kintor regeneration advances with new marketing partnership
9939.HK
- Big deal, bigger doubts: CSPC slides after $18.5 billion pact
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
